Live
BioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haulEndpoints NewsKardigan raises $400M in IPO to back three clinical-stage cardio drugsEndpoints NewsBiogen makes up to $1B deal for secretive anti-inflammatory biotechFierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC gameClinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?AgilentAgilent (A) Has a Consumables-and-Service Analytical Platform Bigger Than a Biotech-Funding Proxy - AlphaStreetClinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting MicrogliaEndpoints NewsFDA gives rejected drugs another chance in post-Makary era10x Genomics Blog10x Genomics (TXG) Launches Cleveland Clinic Partnership For Bladder Cancer Diagnostics - simplywall.st10x Genomics Blog10x Genomics (TXG) Launches Cleveland Clinic Partnership For Bladder Cancer Diagnostics - simplywall.stClinical OMICsAI Discovers Two New Antibiotics for Drug-Resistant GonorrheaClinical OMICsGLP-1 Drugs Reduce Crime-Linked Behavior
PharmaVoice Jan 27, 2026

A potential gene therapy for heart failure is an approach decades in the making

A potential gene therapy for heart failure is an approach decades in the making

Body unavailable. Use the original source.